Clinical Trial Information
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers- Category: Neuroendocrine Cancer, Small Cell Lung Cancer
- Starts: Dec 15, 2023
- Stage: II
- Trial Number: DAREON-05 BI 765432
Principal Investigator: Jose Galeas, MD
Research Nurse: Wendy Blount, RN, MSN
Description of Trial:
DAREON™-5: An open-label, multi-center Phase II dose
selection trial of intravenous BI 764532, a DLL3-targeting T cell
engager, in patients with relapsed/refractory extensive-stage small
cell lung cancer and in patients with other relapsed/refractory
neuroendocrine carcinomas.
Please click here for additional information about this study.
Scope Information
- Applicable Diseases:
- Small Cell Lung Cancer; Neuroendocrine Cancer